Why the study?
What are the pharmacokinetics of oral versus intravenous lisinopril in hospitalized patients with congestive heart failure?
What are the pharmacokinetics of oral versus intravenous lisinopril in hospitalized patients with congestive heart failure?
Lisinopril exhibits reduced absorption and altered disposition in patients with congestive heart failure, suggesting disease state and age may affect its pharmacokinetics.
Answers are grounded in this paper and cite their sources.
Alerts to potential under-exposure with oral lisinopril in heart failure; extends pharmacokinetic data to this population.
The pharmacokinetics of the angiotensin converting enzyme inhibitor, lisinopril, were studied in an open, randomized, balanced, two-period, crossover design in 12 in-patients with stable, chronic congestive heart failure (CHF). 2. To evaluate the pharmacokinetics of lisinopril in CHF, lisinopril was administered orally (10 mg) and intravenously (5 mg) in each patient. Each dose was followed by a 72 h period with frequent blood sampling and fractional urine collections for radioimmunoassay of lisinopril. 3. Mean urinary recovery of lisinopril was 15 and 88% following oral and intravenous administration, respectively; absorption/bioavailability of lisinopril based on urinary recovery ratios was 16%, less than that found in normal subjects. 4. Serum concentrations of lisinopril following intravenous administration were higher in this study than those previously observed in normal subjects. 5. The results of this study suggest a reduced absorption of lisinopril in CHF and altered disposition, possibly associated with age as well as the disease state.
No takes yet. Share an insight, caveat, or question.
Till et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: